ISTH 2025 Spotlight: HOPE-B Trial Highlights Sustained Efficacy of Gene Therapy for Hemophilia B
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X:
“ISTH 2025 Highlight: Our HOPE-B study results were brilliantly presented by Dr. Steven Pipe at ISTH 2025, showcasing 4-year durability data in haemophilia B gene therapy.
Study Overview
The phase 3 HOPE-B trial evaluated a single IV dose of etranacogene dezaparvovec (AAV5-FIX Padua) in adults with haemophilia B (FIX ≤2 IU/dL).
N = 54; Responders = 52
Key Efficacy Results
· ↓ 81% in annualized bleeding rate (ABR) (months 7–48 vs. baseline)
· ↓ 90% in ABR at Year 4 vs. lead-in period
· ↓ 98% in mean exogenous FIX use (IU/year) at Year 4
· 98% of participants remained prophylaxis-free through 4 years
· 37% required zero exogenous FIX infusions over 4 years
Factor IX (FIX) Expression
· Mean FIX activity: 37.4% at Year 4
· 83% of responders maintained FIX levels 12–100 IU/dL at 4 years
· Stable expression over 4 years → near-normal hemostasis
Safety Profile
· 96 treatment-related adverse events (TRAEs) over 4 years
· 96% occurred in first 6 months
· Most frequent: ALT↑ (18.5%), headache, flu-like illness
· No FIX inhibitors
· No thrombotic events
· No AAV5-associated genotoxicity or persistent late hepatotoxicity
Clinical Implications
· Single-dose gene therapy led to durable FIX expression and sustained reduction in bleeding and FIX use for ≥4 years
· Majority achieved and maintained prophylaxis freedom
· Favorable safety profile with minimal late events
· Ongoing follow-up remains important for long-term assessment
Congratulations to Steve Pipe and the co-authors.”
Stay updated with Hemostasis Today.
-
Sep 7, 2025, 16:14Paddy Barret on Thin Cap Fibroatheroma's Outcomes
-
Sep 6, 2025, 14:04Chokri Ben Lamine – VTE Prophylaxis in Pregnancy (ASH 2018 Guidelines)
-
Sep 6, 2025, 13:48The Body Explained on Blood Clotting Pathways
-
Sep 5, 2025, 14:06Thrombosis Update: VTE Death Rate 3X Higher in Los Angeles Jails Than General Population
-
Sep 5, 2025, 10:59New Study Featured by Rare Disease Advisor Reveals Quality-of-Life Challenges in Hemophilia
-
Sep 7, 2025, 17:19Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
-
Sep 6, 2025, 16:43Khaled Musallam: de-LIGHT Study on Use of Lifetime Anemia and Iron Control Index (LAICI) in Thalassemia Treatment
-
Sep 6, 2025, 15:06Managing Gynecologic Bleeding in Anticoagulated Patients: Toolkit Co-Authored by Divyaswathi Citla Sridhar
-
Sep 6, 2025, 14:30Mattia Galli on Whether Reduction in MACE Really Depicts Situation in Spontaneous MI or Death post-PCI
-
Sep 6, 2025, 13:55Patrick Cieran Gallogly and Colleagues on Atypical Symptoms in TIA and Minor Stroke
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 7, 2025, 17:30Louise Bannon Invites You To Join The ''Blood Clot Busters'' Series Uncovering The Truth About Thrombosis
-
Sep 7, 2025, 16:34Outstanding! Mishaal Munir Contributes to 8 Posters and Highlights Her Project in an Oral Presentation at SOHO 2025
-
Sep 7, 2025, 16:01Congratulations to Bart Loeys on Receiving Doctor Honoris Causa!
-
Sep 6, 2025, 14:09Erin VanDyke: Shifting Attention Upstream in VTE Care Through NBCA Centers of Excellence
-
Sep 6, 2025, 12:02Caitlin Raymond on Kairos in Medicine: How Curiosity Sustains Physicians and Prevents Burnout